fined indication with an established market and a medical need, and we conservatively model 33% probability of approval and expect launch in 2020. Solifenacin DRG granules for overactive bladder Veru's urology pipeline for 505(b)(2) pathway includes solifenacin DRG granules for the treatment of overactive bla

in DRS, slow release granules, and Tamsulosin XR capsules for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018), Solifenacin DRG, slow release granules, for overactive bladder (urge incontinence, urgency and frequency of urination) (NDA planned 2019), Tadalafil/finasteride co